KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:开放图源暂不可得 入排置信度 0.98

Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform Trial.

Alessio Crippa, Bram De Laere, Andrea Discacciati, Berit Larsson, Maria Persson, Susanne Johansson, Sanne D'hondt, Marie Hjälm-Eriksson, Linn Pettersson, Gunilla Enblad, Anders Ullén, Nicolaas Lumen, Camilla Thellenberg Karlsson, Johan Sandzén, Elin Jänes, Christophe Ghysel, Martha Olsson, Brieuc Sautois, Peter Schatteman, Wendy De Roock, Siska Van Bruwaene, Ingrida Verbiene, Jochen Darras, Els Everaert, Daan De Maeseneer, Mats Anden, Michiel Strijbos, Daisy Luyten, Ashkan Mortezavi, Jan Oldenburg, Piet Ost, Johan Lindberg, Henrik Grönberg, Martin Eklund, ProBio Investigators

Eur Urol Oncol 8(6) 1486-1495

PMID40263079
PMCID-
DOI10.1016/j.euo.2025.02.002
发表日期2025-04-22
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

BACKGROUND AND OBJECTIVE: The aim of this study was to evaluate the prognostic value of undetectable circulating tumor DNA (ctDNA) and the dose-response relationship between ctDNA levels and survival outcomes in metastatic castration-resistant prostate cancer (mCRPC). METHODS: We analyzed data for patients enrolled in the ProBio trial up to November 2022 who received an androgen receptor pathway inhibitor or taxane. We compared survival outcomes between patients with undetectable ctDNA and those with detectable ctDNA randomized to physician's choice or investigational arms. Time to no longer clinically benefiting (NLCB) and overall survival (OS) were assessed using Bayesian survival models, with results reported as survival time ratios (STRs). Dose-response relationships were estimated using spike-at-zero models. KEY FINDINGS AND LIMITATIONS: A total of 220 patients were included, of whom 139 had detectable ctDNA (56 in the physician's choice arm, 83 in investigational arms) and 81 had undetectable ctDNA. In comparison to the undetectable ctDNA group, the physician's choice arm had 60% shorter time to NLCB (STR 0.40, 90% credible interval [CrI] 0.31-0.51) and 51% shorter OS (STR 0.49, 90% CrI 0.38-0.61). Similar results were observed in comparison to the investigational arms. Dose-response analysis revealed that the undetectable ctDNA group had twofold longer time to NLCB (STR 2.05, 90% CrI 1.66-2.57) and 1.6-fold longer OS (STR 1.63, 90% CrI 1.33-2.05) in comparison to the subgroup with a ctDNA fraction of 2.5%. Every 10-point increment in the ctDNA fraction corresponded to a 10% reduction in NLCB and OS times. CONCLUSIONS AND CLINICAL IMPLICATIONS: Undetectable ctDNA at baseline predicts superior prognosis in mCRPC, suggesting potential for treatment de-escalation and less intensive monitoring for this subgroup of patients. This trial is registered on ClinicalTrials.gov as NCT03903835.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。